ECSP13013038A - Inhibidores sustituidos de acetil-coa carboxilasa - Google Patents

Inhibidores sustituidos de acetil-coa carboxilasa

Info

Publication number
ECSP13013038A
ECSP13013038A ECSP13013038A ECSP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A EC SP13013038 A ECSP13013038 A EC SP13013038A
Authority
EC
Ecuador
Prior art keywords
coa
carboxilasa
acetil
inhibitors
replaced
Prior art date
Application number
Other languages
English (en)
Inventor
Robert Lee Dow
Jr James Alfred Southers
David Andrew Griffith
David James Edmonds
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP13013038A publication Critical patent/ECSP13013038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un compuesto de Fórmula (I)Fórmula (I)o una sal del mismo aceptable desde el punto de vista farmacéutico; donde G esR1, R2 y R3 son como se describe en la presente; composiciones farmacéuticas del mismo; y el uso del mismo en el tratamiento de enfermedades, afecciones o trastornos modulados por la inhibición de una enzima(s) acetil-CoA carboxilasa en un animal.
ECSP13013038 2011-04-22 2013-11-22 Inhibidores sustituidos de acetil-coa carboxilasa ECSP13013038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22

Publications (1)

Publication Number Publication Date
ECSP13013038A true ECSP13013038A (es) 2014-01-31

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13013038 ECSP13013038A (es) 2011-04-22 2013-11-22 Inhibidores sustituidos de acetil-coa carboxilasa

Country Status (43)

Country Link
US (4) US8802688B2 (es)
EP (1) EP2699576B1 (es)
JP (1) JP5657174B2 (es)
KR (1) KR101567659B1 (es)
CN (2) CN106117205B (es)
AP (1) AP3499A (es)
AR (1) AR086198A1 (es)
AU (1) AU2012245996B2 (es)
CA (1) CA2831380C (es)
CL (1) CL2013002794A1 (es)
CO (1) CO6801757A2 (es)
CR (1) CR20130464A (es)
CU (1) CU24164B1 (es)
CY (1) CY1117122T1 (es)
DK (1) DK2699576T3 (es)
DO (1) DOP2013000243A (es)
EA (1) EA022375B1 (es)
EC (1) ECSP13013038A (es)
ES (1) ES2561452T3 (es)
GE (1) GEP20166474B (es)
GT (1) GT201300258A (es)
HR (1) HRP20151397T1 (es)
HU (1) HUE028602T2 (es)
IL (1) IL228949A (es)
MA (1) MA35061B1 (es)
ME (1) ME02312B (es)
MX (1) MX348860B (es)
MY (1) MY162167A (es)
NI (1) NI201300111A (es)
NZ (1) NZ616156A (es)
PE (1) PE20141187A1 (es)
PH (1) PH12013501941A1 (es)
PL (1) PL2699576T3 (es)
PT (1) PT2699576E (es)
PY (1) PY1218709A (es)
RS (1) RS54526B1 (es)
SG (1) SG194142A1 (es)
SI (1) SI2699576T1 (es)
TN (1) TN2013000393A1 (es)
TW (1) TWI464171B (es)
UA (1) UA107753C2 (es)
UY (1) UY34027A (es)
WO (1) WO2012143813A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
KR102243637B1 (ko) 2013-03-14 2021-04-26 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 진통 화합물
HK1221662A1 (zh) 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制剂和其用途
MX2015015422A (es) 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
JPWO2015056782A1 (ja) 2013-10-17 2017-03-09 塩野義製薬株式会社 新規アルキレン誘導体
EP3080072A4 (en) * 2013-12-12 2017-07-19 Kalyra Pharmaceuticals, inc. Bicyclic alkyl compounds and synthesis
WO2015134710A1 (en) * 2014-03-07 2015-09-11 Kalyra Pharmaceuticals, Inc. Propellane derivates and synthesis
CA2892342C (en) 2014-05-22 2016-11-01 Sylvain-Paul Morency Tool and method for layer depalletizing
WO2016044331A1 (en) 2014-09-17 2016-03-24 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
HK1255689A1 (en) * 2015-12-31 2019-08-23 北京谷神生命健康科技有限公司 Triacetyl-3-hydroxyphenyladenosine and application in preparing pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
MX389668B (es) 2017-05-15 2025-03-20 Recurium Ip Holdings Llc Compuestos biciclo[1.1.1]pentilo sustituidos y uso de los mismos para el tratamiento del dolor y fiebre.
IL313710A (en) 2017-11-21 2024-08-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途
CN120457124A (zh) * 2022-12-30 2025-08-08 苏州浦合医药科技有限公司 Prmt5-mta抑制剂
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
WO2025036472A1 (en) * 2023-08-16 2025-02-20 Pharmaengine, Inc. Spirocyclic mta-cooperative prmts inhibitor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
JP4104983B2 (ja) 2001-02-28 2008-06-18 メルク エンド カムパニー インコーポレーテッド メラノコルチン−４受容体作動薬としてのアシル化ピペリジン誘導体
EP1478437B1 (en) 2002-02-27 2005-08-31 Pfizer Products Inc. Acc inhibitors
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
BRPI0510284A (pt) 2004-05-12 2007-10-30 Pfizer Prod Inc derivados de prolina e seu uso como inibidores da dipeptidil peptidase iv
US20050267221A1 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
AP2006003768A0 (en) 2004-05-25 2006-10-31 Pfizer Prod Inc TetraazabenzoÄeÜazulene derivatives and analogs tehereof
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
BRPI0613427A2 (pt) 2005-07-19 2012-10-30 Merck & Co Inc composto ou seu sal ou éster, composição farmacêutica, agente terapêutico, e , uso do composto ou seu sal ou éster
US20100160255A1 (en) 2005-07-29 2010-06-24 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
DE602006019304D1 (de) 2005-11-18 2011-02-10 Merck Sharp & Dohme Spirohydantoin-aryl-cgrp-rezeptorantagonisten
JP2009526868A (ja) 2006-02-15 2009-07-23 アボット・ラボラトリーズ 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用
ES2487967T3 (es) 2006-04-20 2014-08-25 Pfizer Products Inc. Compuestos amido heterocíclicos condensados con fenilo para la prevención y el tratamiento de enfermedades mediadas por la glucoquinasa
AU2007326950B2 (en) 2006-11-29 2010-10-14 Pfizer Products Inc. Spiroketone acetyl-CoA carboxylase inhibitors
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
JPWO2008102749A1 (ja) * 2007-02-20 2010-05-27 武田薬品工業株式会社 複素環化合物
CA2683695C (en) 2007-04-12 2013-06-18 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h,4h,6h) carbaldehyde derivatives
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
US8318762B2 (en) 2008-05-28 2012-11-27 Pfizer Inc. Pyrazolospiroketone acetyl-CoA carboxylase inhibitors
WO2009144555A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
JP5501256B2 (ja) * 2008-07-04 2014-05-21 Ｍｓｄ株式会社 新規スピロクロマノンカルボン酸
EP2310015A4 (en) 2008-07-14 2011-10-26 Cropsolution Inc ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF
US20110130365A1 (en) 2008-07-29 2011-06-02 Benbow John W Fluorinated Heteroaryls
AP2728A (en) 2008-08-28 2013-08-31 Pfizer Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
WO2010086820A1 (en) 2009-02-02 2010-08-05 Pfizer Inc. 4-amino-5-oxo-7, 8-dihydropyrimido [5,4-f] [1,4] oxazepin-6 (5h) -yl) phenyl derivatives, pharmaceutical compositions and uses thereof
CA2754685A1 (en) 2009-03-11 2010-09-16 Pfizer Inc. Substituted indazole amides
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
EP2408780A2 (en) 2009-03-20 2012-01-25 Pfizer Inc. 3-oxa-7-azabicycloý3.3.1¨nonanes
US20120052130A1 (en) 2009-05-08 2012-03-01 Pfizer Inc. Gpr 119 modulators
CA2759843A1 (en) 2009-05-08 2010-11-10 Pfizer Inc. Gpr 119 modulators
AP2799A (en) 2009-06-05 2013-11-30 Pfizer 1-(Piperidin-4-YL)-pyrazole derivatives as GPR 119modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
CN102695708B (zh) * 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
US20120225900A1 (en) * 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
RS55224B1 (sr) * 2010-09-30 2017-02-28 Pfizer N1-pirazolospiroketon acetil-coa karboksilaza inhibitori

Also Published As

Publication number Publication date
PL2699576T3 (pl) 2016-05-31
US8802688B2 (en) 2014-08-12
UA107753C2 (xx) 2015-02-10
CR20130464A (es) 2013-10-16
MX348860B (es) 2017-06-30
KR101567659B1 (ko) 2015-11-09
MY162167A (en) 2017-05-31
EP2699576A1 (en) 2014-02-26
CN103492388A (zh) 2014-01-01
DOP2013000243A (es) 2013-12-31
CY1117122T1 (el) 2017-04-05
AP3499A (en) 2015-12-31
PH12013501941A1 (en) 2021-06-23
PT2699576E (pt) 2016-03-09
RS54526B1 (sr) 2016-06-30
PE20141187A1 (es) 2014-09-18
HRP20151397T1 (hr) 2016-01-15
GEP20166474B (en) 2016-05-10
HUE028602T2 (hu) 2016-12-28
TWI464171B (zh) 2014-12-11
CN106117205B (zh) 2018-09-21
IL228949A (en) 2016-11-30
SI2699576T1 (sl) 2016-02-29
SG194142A1 (en) 2013-11-29
CU24164B1 (es) 2016-03-31
ES2561452T3 (es) 2016-02-26
AP2013007129A0 (en) 2013-09-30
CN106117205A (zh) 2016-11-16
UY34027A (es) 2013-04-05
JP2014515755A (ja) 2014-07-03
IL228949A0 (en) 2013-12-31
NZ616156A (en) 2014-08-29
CU20130126A7 (es) 2014-01-29
MA35061B1 (fr) 2014-04-03
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
CO6801757A2 (es) 2013-11-29
AU2012245996A1 (en) 2013-10-03
CL2013002794A1 (es) 2013-12-27
US20150336958A1 (en) 2015-11-26
JP5657174B2 (ja) 2015-01-21
TN2013000393A1 (fr) 2015-01-20
PY1218709A (es) 2016-01-01
GT201300258A (es) 2015-06-02
EP2699576B1 (en) 2015-12-09
US20150112068A1 (en) 2015-04-23
EA201391288A1 (ru) 2014-04-30
KR20140015511A (ko) 2014-02-06
TW201305162A (zh) 2013-02-01
MX2013012313A (es) 2014-01-31
DK2699576T3 (en) 2016-02-15
AR086198A1 (es) 2013-11-27
US20120270893A1 (en) 2012-10-25
WO2012143813A1 (en) 2012-10-26
CA2831380C (en) 2016-04-05
AU2012245996B2 (en) 2016-09-01
ME02312B (me) 2016-06-20
EA022375B1 (ru) 2015-12-30
CA2831380A1 (en) 2012-10-26

Similar Documents

Publication Publication Date Title
ECSP13013038A (es) Inhibidores sustituidos de acetil-coa carboxilasa
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
MX2015012822A (es) 3-pirimidin-4-il-oxazolidin-2-onas- como inhibidores del idh mutante.
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
DOP2014000152A (es) Inhibidores de bromodominios
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
UY35395A (es) Inhibidores de bromodominios tetracíclicos
MD4666B1 (ro) Inhibitori ai Syk
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX390051B (es) Antagonistas de ep4.
PE20142450A1 (es) Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors
NZ621471A (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof